Log in

Ciena (NYSE:CIEN) Receives Buy Rating from Rosenblatt Securities

Last updated on Tuesday, June 30th, 2020 by MarketBeat

Ciena (NYSE:CIEN)'s stock had its "buy" rating restated by stock analysts at Rosenblatt Securities in a research note issued on Monday, TipRanks reports. They currently have a $64.00 price objective on the communications equipment provider's stock. Rosenblatt Securities' price objective would suggest a potential upside of 20.41% from the stock's current price.

Several other analysts have also commented on CIEN. Zacks Investment Research raised shares of Ciena from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a research note on Tuesday, March 31st. Northland Securities downgraded shares of Ciena from an "outperform" rating to a "market perform" rating and set a $54.00 price target for the company. in a research report on Thursday, June 4th. They noted that the move was a valuation call. B. Riley downgraded shares of Ciena from a "buy" rating to a "neutral" rating and reduced their price target for the company from $54.00 to $51.00 in a research report on Wednesday, May 13th. MKM Partners upped their price target on shares of Ciena from $54.00 to $62.00 and gave the company a "buy" rating in a research report on Friday, May 22nd. Finally, Morgan Stanley upped their price target on shares of Ciena from $47.00 to $50.00 and gave the company an "equal weight" rating in a research report on Friday, June 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the stock. Ciena has a consensus rating of "Buy" and a consensus price target of $56.30.

CIEN stock opened at $53.15 on Monday. Ciena has a 12 month low of $30.58 and a 12 month high of $57.19. The firm has a market cap of $8.21 billion, a PE ratio of 25.93, a P/E/G ratio of 1.29 and a beta of 0.89. The firm has a 50 day simple moving average of $52.93 and a 200 day simple moving average of $44.84. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.28 and a quick ratio of 2.83.

Ciena (NYSE:CIEN) last released its earnings results on Thursday, June 4th. The communications equipment provider reported $0.76 EPS for the quarter, beating the consensus estimate of $0.49 by $0.27. Ciena had a net margin of 8.78% and a return on equity of 16.18%. The business had revenue of $894.00 million during the quarter, compared to analyst estimates of $889.42 million. During the same period in the prior year, the business earned $0.48 earnings per share. The business's quarterly revenue was up 3.3% on a year-over-year basis. As a group, sell-side analysts expect that Ciena will post 2.6 earnings per share for the current year.

In other news, CFO James E. Moylan, Jr. sold 2,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $52.11, for a total transaction of $104,220.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP David M. Rothenstein sold 2,500 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $52.12, for a total transaction of $130,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,150 shares of company stock valued at $1,706,385. Insiders own 0.95% of the company's stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Wealth Quarterback LLC acquired a new position in shares of Ciena during the 4th quarter worth $17,177,931,000. Alliancebernstein L.P. increased its stake in shares of Ciena by 32.3% during the 1st quarter. Alliancebernstein L.P. now owns 4,255,893 shares of the communications equipment provider's stock worth $169,427,000 after purchasing an additional 1,038,125 shares during the last quarter. State Street Corp grew its stake in Ciena by 2.6% in the 1st quarter. State Street Corp now owns 3,783,454 shares of the communications equipment provider's stock valued at $150,619,000 after buying an additional 96,321 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in Ciena by 6.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 3,166,259 shares of the communications equipment provider's stock valued at $135,167,000 after buying an additional 180,614 shares during the last quarter. Finally, Ion Asset Management Ltd. grew its stake in Ciena by 9.2% in the 1st quarter. Ion Asset Management Ltd. now owns 2,625,524 shares of the communications equipment provider's stock valued at $104,522,000 after buying an additional 221,467 shares during the last quarter. Institutional investors own 88.43% of the company's stock.

Ciena Company Profile

Ciena Corporation provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks worldwide. The company's Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching.

Read More: Compound Interest

Analyst Recommendations for Ciena (NYSE:CIEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Biotech Stocks to Buy and Hold in 2020

Biotech stocks are far from a sure thing. However, towards the end of 2019 several stocks in the sector got a nice lift based on promising new drugs in their pipelines. One of the key ways to measure any biotech stocks is the depth of its pipeline. When a biotech company issues a drug, its stock typically gets a lift because, for a brief period of time, the company has exclusive rights to that stock.

But those rights only last for a period of time. And at that point, generic equivalents can enter the market. Since generic labels typically bring prices down, it can be harmful to the stock unless they have a continuous stream of drugs coming to the market.

And in 2020, the story of biotech companies has been the coronavirus. Several of the leading biotech firms are working either individually or in tandem with other firms to develop vaccines or antiviral therapies to help treat and eventually blunt the spread of the virus which remains foreign to our bodies.

So while a volatile market is typically a clue to stay away from biotech stocks, now may be an ideal time to jump into this sector. And we’ve identified 8 stocks that you can buy today and hold until the end of the year.

View the "8 Biotech Stocks to Buy and Hold in 2020".

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.